Kenvue Inc. (NYSE:KVUE) Shares Sold by Norris Perne & French LLP MI

Norris Perne & French LLP MI lessened its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 1.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 713,582 shares of the company's stock after selling 13,850 shares during the quarter. Norris Perne & French LLP MI's holdings in Kenvue were worth $17,112,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. SRS Capital Advisors Inc. raised its holdings in Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after acquiring an additional 571 shares in the last quarter. Clarity Asset Management Inc. acquired a new position in shares of Kenvue during the fourth quarter valued at $45,000. SBI Securities Co. Ltd. acquired a new position in Kenvue during the 4th quarter valued at about $46,000. Deseret Mutual Benefit Administrators boosted its position in shares of Kenvue by 29.0% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company's stock worth $54,000 after buying an additional 568 shares during the period. Finally, Versant Capital Management Inc boosted its position in Kenvue by 77.9% during the 1st quarter. Versant Capital Management Inc now owns 3,415 shares of the company's stock worth $82,000 after acquiring an additional 1,495 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on KVUE. Piper Sandler increased their price target on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. Barclays upped their price target on Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research report on Monday, May 12th. Canaccord Genuity Group increased their target price on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Redburn Atlantic began coverage on Kenvue in a research note on Thursday, April 10th. They set a "neutral" rating and a $23.50 price target for the company. Finally, UBS Group raised their price target on shares of Kenvue from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Friday, May 9th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $25.33.

Kenvue Price Performance

NYSE:KVUE opened at $21.35 on Thursday. The company has a fifty day moving average price of $23.01 and a 200 day moving average price of $22.45. The stock has a market cap of $40.95 billion, a P/E ratio of 38.81, a PEG ratio of 3.33 and a beta of 0.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 0.86 and a quick ratio of 0.60. Kenvue Inc. has a one year low of $17.67 and a one year high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. The business had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. Kenvue's revenue was down 3.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.28 earnings per share. Analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were paid a dividend of $0.205 per share. The ex-dividend date was Wednesday, May 14th. This represents a $0.82 annualized dividend and a yield of 3.84%. Kenvue's dividend payout ratio is currently 149.09%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.